The objective of this project is to characterize the effect of valbenazine, a vesicular monoamine transporter (VMAT2) inhibitor, on neurotransmitter efflux in the medial prefrontal cortex and dorsal striatum of mice: 1) to relate the neurotransmitter release to the efficacy of valbenazine to treat tardive dyskinesia (TD); 2) to understand the interaction of valbenzaine with antipsychotic drugs used to treat patients with TD; and 3) to generate ideas for possible additional indications for valbenazine.
|Effective start/end date||9/26/16 → 9/26/19|
- Neurocrine Biosciences, Inc. (Agmt 9/26/16)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.